SCHEMBL25901670

SCHEMBL25901670

CN1Cc2cnn(COCC[Si](C)(C)C)c2-c2cccc(NC(=O)OC(C)(C)C)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PRMT5 O14744 2/20 0.33
WDR77 Q9BQA1 2/20 0.33
MAPT P10636 2/20 0.33
PDE5A O76074 1/20 0.32
PDE4A P27815 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE1C Q14123 1/20 0.32
PDE3A Q14432 1/20 0.32
DGAT1 O75907 1/20 0.32
GSK3B P49841 1/20 0.31
DYRK1A Q13627 1/20 0.31
DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29766654 1.00 IDO1 (0.35) IDO1MEN1KMT2APRMT5WDR77
SCHEMBL26967787 0.89 MEN1 (0.37) MEN1KMT2AMAPTDGAT1TP53
SCHEMBL29766583 0.82 IDO1 (0.34) IDO1PRMT5WDR77DRD2NAMPT
SCHEMBL25901668 0.82 IDO1 (0.34) IDO1PRMT5WDR77DRD2NAMPT
SCHEMBL25899572 0.82 IDO1 (0.39) IDO1PRMT5WDR77PDE5APDE4A
SCHEMBL29766668 0.82 IDO1 (0.39) IDO1PRMT5WDR77PDE5APDE4A
SCHEMBL25897633 0.78 TYK2 (0.36) MAPTPDE4B
SCHEMBL25315145 0.78 ALOX5AP (0.32)
SCHEMBL29766585 0.78 ALOX5AP (0.32)
SCHEMBL25897623 0.78 DGAT1 (0.32) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LIMITED (GB) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS TYK2, PDXK, JAK1 IDO1 211/4885MEN1 3083/4885KMT2A 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.